Los Angeles Capital Management LLC Has $52.54 Million Stock Position in Insulet Corporation $PODD

Los Angeles Capital Management LLC boosted its position in shares of Insulet Corporation (NASDAQ:PODD) by 518.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 167,231 shares of the medical instruments supplier’s stock after acquiring an additional 140,169 shares during the period. Los Angeles Capital Management LLC owned approximately 0.24% of Insulet worth $52,541,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Sequoia Financial Advisors LLC lifted its holdings in Insulet by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock valued at $634,000 after purchasing an additional 45 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its holdings in shares of Insulet by 0.6% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock worth $2,222,000 after acquiring an additional 48 shares in the last quarter. Mather Group LLC. boosted its holdings in shares of Insulet by 4.4% in the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock worth $360,000 after acquiring an additional 48 shares in the last quarter. Brooklyn Investment Group grew its position in Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock worth $209,000 after acquiring an additional 52 shares during the last quarter. Finally, Cooper Financial Group increased its holdings in Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 58 shares in the last quarter.

Insulet Trading Down 1.1%

NASDAQ PODD opened at $319.82 on Friday. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock’s 50 day moving average price is $325.06 and its two-hundred day moving average price is $309.40. The stock has a market capitalization of $22.51 billion, a price-to-earnings ratio of 97.21, a PEG ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same quarter in the previous year, the business earned $1.08 earnings per share. Insulet’s quarterly revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Royal Bank Of Canada increased their price target on shares of Insulet from $365.00 to $370.00 and gave the company an “outperform” rating in a research note on Friday. Wolfe Research increased their price objective on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday. Raymond James Financial boosted their target price on Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a research report on Friday. Barclays upped their price target on Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Wells Fargo & Company boosted their price objective on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $368.80.

Insider Buying and Selling

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.